CN104511011A - Daptomycin aseptic powder and preparation method thereof - Google Patents
Daptomycin aseptic powder and preparation method thereof Download PDFInfo
- Publication number
- CN104511011A CN104511011A CN201310453014.4A CN201310453014A CN104511011A CN 104511011 A CN104511011 A CN 104511011A CN 201310453014 A CN201310453014 A CN 201310453014A CN 104511011 A CN104511011 A CN 104511011A
- Authority
- CN
- China
- Prior art keywords
- daptomycin
- bottle
- water
- injection
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010013198 Daptomycin Proteins 0.000 title claims abstract description 74
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 title claims abstract description 74
- 229960005484 daptomycin Drugs 0.000 title claims abstract description 73
- 239000000843 powder Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 22
- 239000002245 particle Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 239000000047 product Substances 0.000 claims description 27
- 230000001954 sterilising effect Effects 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 18
- 239000008215 water for injection Substances 0.000 claims description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 7
- 239000011265 semifinished product Substances 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000005485 electric heating Methods 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims description 3
- -1 hairbrush and scrub Substances 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000000643 oven drying Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000002699 waste material Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 abstract description 10
- 238000005516 engineering process Methods 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract 1
- 238000012856 packing Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical group [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000005429 filling process Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940021392 cubicin Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940032302 daptomycin 500 mg Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to the technical field of medicinal preparations, and concretely relates to a daptomycin aseptic powder and a preparation method thereof. The daptomycin aseptic powder only contains daptomycin and a pH adjusting agent. The technical scheme employs an aseptic split-charging technology for preparing the aseptic powder from daptomycin. Through a lot of experiments, the daptomycin aseptic powder with good stability is obtained by optimizing and improving the prescription and controlling the particle size of raw materials and auxiliary materials. At the same time, on the above basis, the air humidity for split charging is optimized, and thus finally the problems that the powder easily adsorbs moisture and is bad in stability are solved, and the daptomycin aseptic powder, which possesses uniform packing volume and good stability and is suitable for industrialized production, and the preparation method of the powder, are obtained.
Description
Technical field
The invention belongs to pharmaceutical preparations technology field, be specifically related to a kind of daptomycin sterilized powder and preparation method thereof.
Background technology
Daptomycin (Daptomycin) carrys out (Lilly) company original research by gift, the Cyclic lipopeptide antibiotic of Cubist drugmaker exploitation, the end of the year 2003, U.S. FDA is through the listing of quick examination and approval procedures approval injection daptomycin, must believe for trade name CUBICIN(gram), be used for the treatment of the concurrency skin and skin structure infection that are caused by some Gram-positive sensitive strains, as abscess, surgery cut infection and skin ulcer.Daptomycin mechanism of action is different from other antibiotic, and it by upsetting cell membrane to amino acid whose transhipment, thus hinders the biosynthesis of bacteria cell wall Peptidoglycan; In addition, it can also destroy bacterial cell membrane, makes its content leak and kill antibacterial, and therefore antibacterial is to the less generation drug resistance of daptomycin.
Chinese invention patent application prospectus CN1616083A discloses daptomycin freeze-dried dose of a kind of injection and preparation method thereof.In this technical scheme, daptomycin is added a certain amount of sodium hydroxide, pH adjusting agent, after being made into certain density solution with water for injection, lyophilization 30-60 hour obtained finished product is carried out in fill in control antibiotic cillin bottle.This patent application is identical with import prescription, and technique is also basically identical, but there are some inferior positions.First, daptomycin is slightly soluble in water, and unstable, easily degrades, and in freeze-dried powder production process, medicine needs first to be dissolved in water for injection and is made into certain density solution, in the process, drug degradation is very fast, and related substance increases, and brings certain security risk to medication.Secondly, freeze-drying process needs 30-60 hour, and the process such as to make up a prescription before adding, consuming time longer, freeze dryer power consumption is large, and cost of drugs rises, and adds the financial burden of patient, is unfavorable for the popularization of industrialization technology.
In view of all deficiencies of freeze-dried powder, technical staff often selects to adopt aseptic subpackaged technology that daptomycin is prepared into sterilized powder, but in aseptic subpackaged process, there is the daptomycin very easily moisture absorption, after the moisture absorption, viscosity becomes large, and mobility is deteriorated, and directly affects the subpackage uniformity of medicine, cause and can subpackage rate reduce, have no the relevant report of Tobramycin sterilized powder in prior art for this reason.
Summary of the invention
In order to overcome the defect of prior art, inventor providing a kind of stable daptomycin sterilized powder and being beneficial to the daptomycin sterilized powder preparation method of suitability for industrialized production.
One of the object of the invention discloses a kind of prescription of daptomycin sterilized powder.
Described daptomycin sterilized powder, is made up of the component of following weight portion:
Daptomycin 100-500mg
PH adjusting agent 10-50mg
Above-mentioned daptomycin raw material particle size is 50-150 μm.
The present invention carries out preferably described daptomycin raw material particle size, and preferably, above-mentioned daptomycin raw material particle size is 70-100 μm.
The purposes of pH adjusting agent regulates medicinal liquid pH value when being to redissolve, and promotes the rapid solution of active component daptomycin, and ensures its stability during use.So the present invention carries out preferably described pH adjusting agent, and preferably, above-mentioned pH adjusting agent is the one in sodium hydroxide, sodium bicarbonate.The present invention also carries out preferably the consumption of described pH adjusting agent, and preferably, the consumption of above-mentioned pH adjusting agent is 25-40mg.
The present invention's second object is the preparation method of openly a kind of daptomycin sterilized powder.
1) wash bottle: after cillin bottle manager bottle, enter wash bottle conveyer belt, inject inside and outside pure water, hairbrush and scrub, spray inside and outside water for injection, filtrated air blows back water, enters tunnel oven sterilizing; Air pressure 0.15Mpa, pure water, water for injection pressure 0.2Mpa; Pure water 0.45um metre filter, water for injection 0.22um metre filter;
2) bottle sterilizing: successively by electric heating self-controlling instrument, fan switch is opened, treats that temperature rises to: DEG C sterilizing section T2:300-320 DEG C, preheating section T1:250-300; DEG C cooling section T4:250-120 DEG C, soaking zone T3:320-350; Less than outlet temperature T5:40 DEG C; Bottle can be entered: enter bottle process and keep said temperature; 100 grades, baking oven bottle outlet local;
3) plug washing sterilizing: plug pours washing tank into, pure water rinsing 30 minutes under compressed air stirs, water for injection rinsing 15 minutes.Pull out and be contained in stainless steel disc and enter oven drying sterilizing; Baking temperature 121 DEG C, 0.5 hour drying time; Sterilising temp 121 DEG C, sterilization time 20 minutes; Pure water, water for injection are respectively through 0.45um, 0.22um metre filter;
4) mixed: in aseptic weighing area, the daptomycin of recipe quantity and pH adjusting agent to be crossed 80 ~ 100 mesh sieves, Homogeneous phase mixing;
5) subpackage: empty bottle, plug, after clarity test is qualified, start subpackage; Require more than subpackage air pressure 0.05Mpa, vacuum 600mmHg post, be filled under relative humidity is 15%-40% condition in cillin bottle, be filled with nitrogen; The medicine installed is divided to prop up the semi-finished product fastened through loading amount, plug;
6) gland: semi-finished product carry out rolling lid, lamp inspection, after waste product removing, packaging, labeling.
Homogeneous in order to ensure the filling effect of medicine and adjuvant, inventor optimizes the control of ambient humidity and daptomycin raw material particle size in preparation process.In addition, inventor utilizes the control of ambient humidity to solve daptomycin raw material and pH adjusting agent moisture absorption in preparation process, thus ensure that the qualified and stability of the moisture limit of final products.
The present invention carries out preferably damp condition in described filling process, and preferably, in above-mentioned filling process, environmental damp condition is relative humidity is 25%-35%.
The present invention carries out preferably described daptomycin raw material particle size, and preferably, above-mentioned filling daptomycin raw material particle size used is 50-150 μm; It is further preferred that above-mentioned daptomycin raw material particle size is 70-100 μm.
Inventor also finds to utilize the technology being filled with nitrogen, the contact effectively can isolating daptomycin and oxygen prevents its oxidative degradation, and product can be entered by the moisture limited to a certain extent in plug, ensure that in the long-time put procedure of product, water tariff collection is in lower level.
The present invention compared with prior art, has following outstanding advantage.
Technical solutions according to the invention adopt aseptic subpackaged technology that daptomycin is prepared into sterilized powder.Through great many of experiments, Optimal improvements of the present invention prescription also adopts the particle diameter controlling supplementary material, obtains the daptomycin sterilized powder had good stability.Meanwhile, on this basis, the present invention optimizes again air humidity during subpackage, finally solves the problem of easy moisture absorption poor stability, obtains the daptomycin sterilized powder that loading amount is even, have good stability.
One of advantage of the present invention is without processes such as dissolving, filtration, lyophilizing, medicine does not contact with water in whole production process, subpackage directly can be mixed homogeneously with pH adjusting agent, avoid the hydrolysis of medicine, improve drug quality, namely the medicine prepared by the present invention, daptomycin medicine is almost without degraded, related substance is starkly lower than commercially available dried frozen aquatic products, long-time stability are also better than commercially available product, drug safety risk reduces, and effectively overcomes the deficiency existing for solution type injection agent and freeze-dried powder.
Another advantage of the present invention is that production technology is simple; do not need the processes such as freeze dryer lyophilizing, degerming membrane filtration; make up a prescription consuming time short; not only the production time by 3-4 days/batch significantly foreshortening to 1 day/batch, and reduce energy consumption, production cost also reduces greatly; alleviate the financial burden of patient, be beneficial to large-scale production and reduce drug price.
Detailed description of the invention
Further illustrate the present invention by the following examples, but these embodiments do not limit the present invention in any way.
Embodiment 1
Prescription:
Daptomycin 100mg
Sodium hydroxide 10mg
Preparation method is as follows:
1) wash bottle: after cillin bottle manager bottle, enter wash bottle conveyer belt, inject inside and outside pure water, hairbrush and scrub, spray inside and outside water for injection, filtrated air blows back water, enters tunnel oven sterilizing; Air pressure 0.15Mpa, pure water, water for injection pressure 0.2Mpa; Pure water 0.45um metre filter, water for injection 0.22um metre filter;
2) bottle sterilizing: successively by electric heating self-controlling instrument, fan switch is opened, treats that temperature rises to: DEG C sterilizing section T2:300-320 DEG C, preheating section T1:250-300; DEG C cooling section T4:250-120 DEG C, soaking zone T3:320-350; Less than outlet temperature T5:40 DEG C; Bottle can be entered: enter bottle process and keep said temperature; 100 grades, baking oven bottle outlet local;
3) plug washing sterilizing: plug pours washing tank into, pure water rinsing 30 minutes under compressed air stirs, water for injection rinsing 15 minutes.Pull out and be contained in stainless steel disc and enter oven drying sterilizing; Baking temperature 121 DEG C, 0.5 hour drying time; Sterilising temp 121 DEG C, sterilization time 20 minutes; Pure water, water for injection are respectively through 0.45um, 0.22um metre filter;
4) mixed: in aseptic weighing area, the daptomycin of recipe quantity and sodium hydroxide to be crossed 80 ~ 100 mesh sieves, daptomycin size controlling at 50-70 μm, Homogeneous phase mixing;
5) subpackage: empty bottle, plug, after clarity test is qualified, start subpackage; Require more than subpackage air pressure 0.05Mpa, vacuum 600mmHg post, be filled under relative humidity is 40% condition in cillin bottle, be filled with nitrogen; The medicine installed is divided to prop up the semi-finished product fastened through loading amount, plug;
6) gland: semi-finished product carry out rolling lid, lamp inspection, after waste product removing, packaging, labeling.
Embodiment 2
Prescription:
Daptomycin 300mg
Sodium hydroxide 35mg
Preparation method:
Other steps are with embodiment 1, and wherein the daptomycin size controlling of step 4) is at 70-100 μm, and pH adjusting agent is sodium hydroxide, the relative humidity 25% of step 5).
Embodiment 3
Prescription:
Daptomycin 300mg
Sodium bicarbonate 50mg
Preparation method:
Other steps are with embodiment 1, and wherein the daptomycin size controlling of step 4) is at 70-100 μm, and pH adjusting agent is sodium bicarbonate, the relative humidity 35% of step 5).
Embodiment 4
Prescription:
Daptomycin 500mg
Sodium hydroxide 50mg
Preparation method:
Other steps are with embodiment 1, and wherein the daptomycin size controlling of step 4) is at 60-90 μm, and pH adjusting agent is sodium hydroxide, the relative humidity 30% of step 5).
Embodiment 5
Prescription:
Daptomycin 200mg
Sodium bicarbonate 35mg
Preparation method:
Other steps are with embodiment 1, and wherein the daptomycin size controlling of step 4) is at 120-150 μm, and pH adjusting agent is sodium bicarbonate, the relative humidity 15% of step 5).
Comparative example 6
Prescription:
Daptomycin 200mg
Sodium dihydrogen phosphate 35mg
Preparation method:
Other steps are with embodiment 1, and wherein the daptomycin size controlling of step 4) is at 70-100 μm, and pH adjusting agent is sodium dihydrogen phosphate, the relative humidity 25% of step 5).
Comparative example 7:
Prescription:
Daptomycin 200mg
Sodium bicarbonate 35mg
Preparation method:
Other steps are with embodiment 1, and wherein the daptomycin size controlling of step 4) is at 70-100 μm, and pH adjusting agent is sodium bicarbonate, the relative humidity 50% of step 5).
Comparative example 8
Prescription:
Daptomycin 200mg
Sodium bicarbonate 35mg
Preparation method:
Other steps are with embodiment 1, and wherein the daptomycin size controlling of step 4) is at 170-200 μm, and pH adjusting agent is sodium bicarbonate, the relative humidity 25% of step 5).
Test example 9. product quality is investigated
Under embodiment 1-5 products obtained therefrom and comparative example 6-8, commercially available injection daptomycin are placed in the same terms, (25 DEG C, RH60%) carry out quality versus, the results are shown in Table 1.
Table 1. quality versus
By table 1, can find out the subpackage uniformity RSD<2.0% of product of the present invention, homogeneity is better; Content and the related substance of product of the present invention are all better than commercially available product, illustrate that product quality of the present invention is outstanding.The pH adjusting agent of embodiment 6 has selected sodium dihydrogen phosphate, can not promote the rapid solution of daptomycin, and have impact on its stability related substance increases obviously; High humidity time prepared by embodiment 7, when causing subpackage, relative humidity is higher, the product moisture absorption, and final subpackage uniformity RSD becomes large; Embodiment 8 due to raw material particle size comparatively large, subpackage uniformity reduces, and related substance also obviously increases because of the moisture absorption.
Test example 10. product long-time stability are investigated
Under embodiment 1-5 products obtained therefrom and comparative example 6-8, commercially available injection daptomycin are placed in the same terms (25 DEG C, RH60%) long-term placement carries out long-time stability investigation in 24 months, detect in sampling in the 3rd, 6,12,24 month, test item is clarity and color, content and related substance, relatively its stability, the results are shown in Table 2.
Table 2. long-time stability investigate result
Can be found out by table 2 long-term stable experiment, clear, colorless after daptomycin sterilized powder product prepared by the present invention dissolves, product drug content and related substance change, all much smaller than comparative example 6-8 and commercially available product, show that product stability of the present invention is good.
Test example 11. product accelerated stability is investigated
Under embodiment 1-5 products obtained therefrom and comparative example 6-8, commercially available injection daptomycin are placed in the same terms (50 DEG C, RH85%) January is carried out accelerated stability investigation in placement, detect in sampling in the 10th, 20,30 day, test item is clarity and color, content and related substance, relatively its stability, the results are shown in Table 3.
Table 3. accelerated stability investigates result
Can be found out by table 3 accelerated stability test, clear, colorless after daptomycin sterilized powder product prepared by the present invention dissolves, the change of drug content and related substance, all much smaller than comparative example 6-8 and commercially available product, shows that product stability of the present invention is good.
Claims (6)
1. a daptomycin sterilized powder, is characterized in that: be made up of the component of following weight portion:
Daptomycin 100-500mg
PH adjusting agent 10-50mg
Wherein, the particle diameter of described daptomycin is 50-150 μm.
2. daptomycin sterilized powder according to claim 1, is characterized in that daptomycin particle diameter being 70-100 μm.
3. daptomycin sterilized powder according to claim 1, is characterized in that described pH adjusting agent is the one in sodium hydroxide, sodium bicarbonate.
4. a preparation method for daptomycin sterilized powder, is characterized in that:
1) wash bottle: after cillin bottle manager bottle, enter wash bottle conveyer belt, inject inside and outside pure water, hairbrush and scrub, spray inside and outside water for injection, filtrated air blows back water, enters tunnel oven sterilizing; Air pressure 0.15Mpa, pure water, water for injection pressure 0.2Mpa; Pure water 0.45um metre filter, water for injection 0.22um metre filter;
2) bottle sterilizing: successively by electric heating self-controlling instrument, fan switch is opened, treats that temperature rises to: DEG C sterilizing section T2:300-320 DEG C, preheating section T1:250-300; DEG C cooling section T4:250-120 DEG C, soaking zone T3:320-350; Less than outlet temperature T5:40 DEG C; Bottle can be entered: enter bottle process and keep said temperature; 100 grades, baking oven bottle outlet local;
3) plug washing sterilizing: plug pours washing tank into, pure water rinsing 30 minutes under compressed air stirs, water for injection rinsing 15 minutes.Pull out and be contained in stainless steel disc and enter oven drying sterilizing; Baking temperature 121 DEG C, 0.5 hour drying time; Sterilising temp 121 DEG C, sterilization time 20 minutes; Pure water, water for injection are respectively through 0.45um, 0.22um metre filter;
4) mixed: in aseptic weighing area, the daptomycin of recipe quantity and pH adjusting agent to be crossed 80 ~ 100 mesh sieves, Homogeneous phase mixing;
5) subpackage: empty bottle, plug, after clarity test is qualified, start subpackage; Require more than subpackage air pressure 0.05Mpa, vacuum 600mmHg post, be filled under relative humidity is 15%-40% condition in cillin bottle, be filled with nitrogen; The medicine installed is divided to prop up the semi-finished product fastened through loading amount, plug;
6) gland: semi-finished product carry out rolling lid, lamp inspection, after waste product removing, packaging, labeling.
5. daptomycin sterilized powder preparation method according to claim 4, is characterized in that daptomycin particle diameter being 70-100 μm.
6. daptomycin sterilized powder preparation method according to claim 4, is characterized in that described damp condition is 25%-35%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310453014.4A CN104511011A (en) | 2013-09-29 | 2013-09-29 | Daptomycin aseptic powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310453014.4A CN104511011A (en) | 2013-09-29 | 2013-09-29 | Daptomycin aseptic powder and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104511011A true CN104511011A (en) | 2015-04-15 |
Family
ID=52787249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310453014.4A Pending CN104511011A (en) | 2013-09-29 | 2013-09-29 | Daptomycin aseptic powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104511011A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106943587A (en) * | 2016-01-06 | 2017-07-14 | 山东新时代药业有限公司 | A kind of daptomycin freeze-dried powder pin of injection and its preparation technology |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1054537A (en) * | 1989-03-06 | 1991-09-18 | 伊莱利利公司 | Improved diluent formulation for daptomycin |
| CN1404487A (en) * | 2000-01-20 | 2003-03-19 | 卡比斯特制药公司 | High-purity lipopeptide, lipopeptide micelles and preparation method thereof |
| CN1616083A (en) * | 2004-09-01 | 2005-05-18 | 魏雪纹 | Daptomycin freeze-dried preparation for injection and preparing method |
| CN101830970A (en) * | 2009-03-12 | 2010-09-15 | 成都雅途生物技术有限公司 | Purification and preparation method of high-purity Daptomycin |
| WO2011062676A1 (en) * | 2009-11-23 | 2011-05-26 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
| CN102712677A (en) * | 2009-11-23 | 2012-10-03 | 丘比斯特药物股份有限公司 | Lipopeptide compositions and related methods |
-
2013
- 2013-09-29 CN CN201310453014.4A patent/CN104511011A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1054537A (en) * | 1989-03-06 | 1991-09-18 | 伊莱利利公司 | Improved diluent formulation for daptomycin |
| CN1404487A (en) * | 2000-01-20 | 2003-03-19 | 卡比斯特制药公司 | High-purity lipopeptide, lipopeptide micelles and preparation method thereof |
| CN1616083A (en) * | 2004-09-01 | 2005-05-18 | 魏雪纹 | Daptomycin freeze-dried preparation for injection and preparing method |
| CN101830970A (en) * | 2009-03-12 | 2010-09-15 | 成都雅途生物技术有限公司 | Purification and preparation method of high-purity Daptomycin |
| WO2011062676A1 (en) * | 2009-11-23 | 2011-05-26 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
| CN102712677A (en) * | 2009-11-23 | 2012-10-03 | 丘比斯特药物股份有限公司 | Lipopeptide compositions and related methods |
Non-Patent Citations (1)
| Title |
|---|
| 张强等主编: "《药剂学》", 31 January 2005, 北京大学医学出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106943587A (en) * | 2016-01-06 | 2017-07-14 | 山东新时代药业有限公司 | A kind of daptomycin freeze-dried powder pin of injection and its preparation technology |
| CN106943587B (en) * | 2016-01-06 | 2021-06-22 | 山东新时代药业有限公司 | Daptomycin freeze-dried powder injection for injection and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106730017B (en) | A kind of sustained-release antibacterial composite membrane of bootable bone tissue regeneration and preparation method thereof | |
| CN101623285B (en) | Cefmetazole sodium medicament and preparation method thereof | |
| CN102895181B (en) | Method for preparing mezlocillin sodium for injection | |
| CN101606934B (en) | Bendamustine hydrochloride compound | |
| CN101327193A (en) | Lornoxicam freeze-dried injection and preparation method thereof | |
| CN103301131A (en) | Preparation method of piperacillin sodium sulbactam sodium for injection | |
| CN112618496A (en) | Preparation method of azithromycin freeze-dried powder injection for injection | |
| CN101584668A (en) | Bendamustine hydrochloride freeze-dried powder injection | |
| CN103446068B (en) | Bortezomib freeze-dried composition and preparation method thereof | |
| CN104511011A (en) | Daptomycin aseptic powder and preparation method thereof | |
| CN104195091B (en) | The preparation method of a kind of solid biologic microbial inoculum and with the solid biologic microbial inoculum of its preparation | |
| CN101584669A (en) | Melphalan freeze-dried powder injection | |
| CN102885775B (en) | Andrographolide sterile powder and its preparation method | |
| CN102641249A (en) | Preparation method of tigecycline composition | |
| CN106943587A (en) | A kind of daptomycin freeze-dried powder pin of injection and its preparation technology | |
| CN108066338B (en) | Antibiotic composition and preparation method thereof | |
| CN1572296A (en) | Freeze dried vinpocetine powder injection and its preparation process | |
| CN107714664A (en) | Aspirin-Al-lysine for injection freeze drying powder injection and preparation method thereof | |
| CN103301123A (en) | Preparation method for controlling pH (Potential of Hydrogen) of amoxicillin sodium/sulbactam sodium | |
| CN113679672B (en) | Preparation method of high-water-solubility amoxicillin soluble powder | |
| CN102061021B (en) | Method for preparing natural clove extract-containing medical rubber plug used for sterilization and disinfection | |
| CN112190597A (en) | Application of biotransformation bear gall powder in preparation of antipyretic medicine | |
| CN104644572A (en) | High purity clindamycin phosphate powder-injection and preparation process thereof | |
| CN1230175C (en) | Ligustrazine hydrochloride freeze-dried preparation for injection and its preparing method | |
| CN103432121A (en) | Preparation method of amoxicillim sodium and sulbactam sodium for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150415 |
|
| RJ01 | Rejection of invention patent application after publication |